Work

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.8009

Authors: David Planchard, Julien Mazieres, Gregory J. Riely, Charles M. Rudin, Fabrice Barlesi, Elisabeth A. Quoix, Pierre Jean Souquet, Mark A. Socinski, Julie Switzky, Bo Ma, Vicki L. Goodman, Stanley W. Carson, C. Martin Curtis, Michael R. W. Streit, Bruce E. Johnson

Institutions: Institut Gustave Roussy, Hôpital Larrey, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Hôpitaux Universitaires de Strasbourg, Hôpital Lyon Sud, University of Pittsburgh, GlaxoSmithKline (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2328484078

Cites:

Cited by: 109

Related to: 10